Drug Profile

CRB 602

Alternative Names: CRB-602

Latest Information Update: 28 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Panorama Research
Developer Corbus Pharmaceuticals; Panorama Research
Class Antineoplastics; Monoclonal antibodies
Mechanism of Action Transforming growth factor beta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Fibrosis; Solid tumours

Most Recent Events

28 Jul 2025 No recent reports of development identified for preclinical development in Fibrosis in USA
28 Jul 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA
25 Jan 2024 Corbus Pharmaceuticals sends a notice of termination its licence for CRB 602 from Milky Way Biopharma, a subsidiary of Panorama Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com